Latest Market Pricing News

Mindax Limited has locked in a total of A$3.9 million in convertible note funding from Singapore-based L&Y Investment Holdings, contingent on Foreign Investment Review Board approval. The unsecured notes carry 10% interest and could dilute existing shareholders by up to 4.63%.

WCM Global Growth Limited (ASX:WQG) has confirmed its fully franked final dividend for Q4 FY2026 at 2.35 cents per share, with a Dividend Reinvestment Plan (DRP) issue price capped by pre-tax net tangible assets per share.

OMG Group Limited is offering eligible shareholders in Australia and New Zealand a chance to buy up to $30,000 of new shares at a 5.4% discount through a Share Purchase Plan following a recent $1.5 million placement.

A2MP Investments has issued a third supplementary bidder's statement disputing the valuation and assumptions underpinning Canyon Resources' takeover response, highlighting persistent funding uncertainties and project execution risks. The bidder insists its offer remains the sole liquidity option for shareholders ahead of the September 21 deadline.

ZhongNuo has begun a 15-day geological mapping program at Chariot Resources' Iganna lithium project in Nigeria, marking a key step under their binding term sheet. This work precedes a potential drilling campaign contingent on project selection.

EQ Resources Ltd hit a new revenue peak of A$55.1 million in August 2026, boosted by a 34% jump in tungsten production to 19,068 mtu across its Australian and Spanish mines.

Cadence Opportunities Fund (ASX: CDO) is offering eligible shareholders a chance to buy up to $30,000 of shares at a 3.5% discount to market price, following a 30.3% portfolio gain for FY26 and a 41% total shareholder return.

L1 Gold Fund Limited (ASX:LGF) has launched a retail entitlement offer aiming to raise up to $261.7 million by issuing one new share for every three held, priced at $2.25 each. This follows a $254.9 million institutional placement and entitlement offer completed earlier in August.

Cambium Bio has secured FDA agreement on a streamlined single pivotal Phase 3 trial for Elate Ocular®, cutting development costs and timelines. Despite a AUD 4.1 million loss for FY2026, the company strengthened its funding position and manufacturing partnerships ahead of patient dosing targeted for late 2026.

Magellan Infrastructure Fund (Currency Hedged) reported a $73.9 million profit for FY2026, down from $108.1 million the prior year, while boosting distributions to unitholders by over 270%.

Dominion Income Trust 1 (ASX:DN1) delivered a standout performance for the year ended 30 June 2026, generating a 7.32% net return and sharply higher distributions, significantly outperforming its benchmark.

Nanuk New World Fund posted robust gains in the 2026 financial year, with its hedged unit class surging 36.1% and unhedged units rising 27.1%, driven by a global equities portfolio focused on sustainability themes.